Your Thyroid Medication Isn't Working as It Should. Your Genes May Be Why.

CYP2D6 is a hepatic enzyme responsible for breaking down and clearing roughly 25% of all drugs from your body, including many medications that interact with levothyroxine. It’s your body’s cleanup crew for thyroid treatment. When CYP2D6 works normally, levothyroxine and any companion medications stay in your bloodstream long enough to work, then get cleared at the right pace.

If you carry a poor metabolizer variant in CYP2D6, you’re in roughly the 7 to 10% of people with European ancestry who clear drugs much more slowly than expected. This means levothyroxine and any co-medications accumulate to higher levels in your blood, potentially causing overmedication symptoms even at standard doses. Conversely, if you’re an ultra-rapid metabolizer with gene duplications, you clear levothyroxine so quickly that therapeutic levels never build up and you feel perpetually undertreated.

You might notice this as unpredictable symptoms: some days you feel jittery and over-medicated, other days exhausted and under-medicated. You might also struggle if you take antidepressants, beta-blockers, or other medications alongside levothyroxine, because CYP2D6 is responsible for clearing those too. The timing and interactions become chaotic.

CYP2C19 is another key hepatic enzyme, metabolizing levothyroxine and many medications commonly prescribed alongside thyroid treatment, including proton pump inhibitors (PPIs) used for acid reflux. PPIs and levothyroxine are a particularly problematic combination in CYP2C19 poor metabolizers because both drugs compete for the same enzyme. When your CYP2C19 is slow, both drugs pile up in your system.

Roughly 2 to 15% of the population are poor metabolizers of CYP2C19, depending on ancestry. Poor metabolizers accumulate levothyroxine and co-medications to higher levels, potentially triggering thyrotoxic-like symptoms: tremor, heart palpitations, anxiety, and insomnia despite normal or even low TSH. If you’re on a PPI for reflux and taking levothyroxine, this becomes even more critical because the PPI itself impairs levothyroxine absorption, and if you’re a poor metabolizer of the PPI, the whole system breaks down.

You might feel perpetually over-medicated or experience erratic symptom days. Your doctor might lower your levothyroxine dose based on TSH, but the real problem is that you’re not clearing the medication fast enough, and adding a second slow-clearing drug makes it worse.

CYP2C9 metabolizes levothyroxine, NSAIDs, and other anti-inflammatory medications that many hypothyroid patients take for joint pain or autoimmune thyroid disease (Hashimoto’s). It’s another major clearance pathway. In people with normal CYP2C9 function, levothyroxine gets metabolized and cleared efficiently. The dose-to-effect relationship is predictable.

About 5 to 10% of people with European ancestry carry poor metabolizer variants in CYP2C9. Poor metabolizers accumulate levothyroxine and NSAIDs more slowly, leading to higher systemic exposure and a narrower therapeutic window where you feel normal without overdose symptoms. This is especially problematic if you take ibuprofen, naproxen, or other NSAIDs regularly for pain or inflammation, because CYP2C9 becomes the bottleneck for clearing both drugs.

You might feel that your levothyroxine dose never quite settles. You adjust up and feel shaky; you adjust down and feel exhausted. The instability is partly because you’re accumulating medication faster than your body can clear it, and adding NSAIDs to the mix makes it worse.

SLCO1B1 is a cellular transporter protein that moves levothyroxine and other molecules into your liver and other tissues where they can be processed and activated. Think of it as the doorway. If the doorway is narrow or malfunctioning, levothyroxine can’t enter the cells that need to metabolize it. It stays circulating in your bloodstream instead of doing its job.

Roughly 15% of people carry the SLCO1B1 *5 variant (rs4149056 C allele), which reduces this transporter’s function. People with this variant have reduced hepatic uptake of levothyroxine and related molecules, meaning the hormone lingers in your blood without being processed and activated efficiently. Your blood tests might show normal T4 levels, but the hormone isn’t getting into the cells where T3 conversion happens, so you still feel hypothyroid.

You might feel like your levothyroxine dose is never quite enough, even when bloodwork looks normal. You might also struggle with statin medications if you take them, because SLCO1B1 is responsible for transporting statins too. The combination of impaired levothyroxine uptake and statin accumulation can leave you feeling metabolically compromised.

VKORC1 encodes the vitamin K epoxide reductase enzyme, which recycles vitamin K in your body. Vitamin K plays a subtle but important role in thyroid hormone metabolism and the absorption of levothyroxine in the gut. While VKORC1 is most famous as the warfarin target, its role in vitamin K recycling affects how efficiently your body absorbs and utilizes thyroid medication.

Roughly 40% of people with European ancestry carry the VKORC1 -1639G>A A allele, which reduces vitamin K recycling efficiency. People with this variant have impaired vitamin K metabolism, which can reduce levothyroxine absorption in the gut and impair the co-factors needed for T4 to T3 conversion. You might absorb less levothyroxine per dose, requiring higher doses to achieve the same therapeutic effect.

You might notice that your levothyroxine response seems weaker than expected, even though you’re taking it correctly. You might also benefit from adding vitamin K-rich foods or supplements, because supplementing the pathway that your gene has impaired can restore some absorption efficiency. This is one of the few instances where a genetic variant can be partially compensated by targeted nutrition.

MTHFR encodes the methylenetetrahydrofolate reductase enzyme, which converts dietary folate into its active, methylated form. This active folate is essential for dozens of metabolic pathways, including the conversion of levothyroxine’s T4 into the active T3 hormone your cells actually use. If your MTHFR is impaired, you can’t generate enough methylated folate, and the entire thyroid activation cascade slows down.

Roughly 40% of people with European ancestry carry the MTHFR C677T variant, which reduces this enzyme’s efficiency by 35 to 70%. Poor MTHFR function means your body struggles to activate the folate co-factors needed for T4 to T3 conversion, so even adequate levothyroxine levels don’t translate into enough active thyroid hormone in your cells. You take your medication, TSH drops to normal, but you still feel hypothyroid because the hormone isn’t being fully activated.

You might feel perpetually cold, fatigued, brain-fogged, and metabolically sluggish despite a normal or even suppressed TSH. You might also struggle with other folate-dependent processes like methylation, detoxification, and neurotransmitter synthesis, creating a cascade of downstream symptoms that seem unrelated to thyroid function but all stem from the same genetic bottleneck.